AR029178A1 - Compuesto antagonista selectivo del receptor de adenosina a2b, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento - Google Patents
Compuesto antagonista selectivo del receptor de adenosina a2b, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamentoInfo
- Publication number
- AR029178A1 AR029178A1 ARP000104523A ARP000104523A AR029178A1 AR 029178 A1 AR029178 A1 AR 029178A1 AR P000104523 A ARP000104523 A AR P000104523A AR P000104523 A ARP000104523 A AR P000104523A AR 029178 A1 AR029178 A1 AR 029178A1
- Authority
- AR
- Argentina
- Prior art keywords
- adenosine
- manufacture
- antagonist compound
- receiver
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
Abstract
Un compuesto antagonista selectivo del receptor de adenosina A2B de la formula (1), en donde R es un grupo amina alifático o cicloalifático, o una sal farmacéuticamente aceptable del mismo, y una sal farmacéuticamente aceptable del mismo. Los compuestos de formula (1) se pueden usar para tratar, entre otras indicaciones, asma y diarrea. Además se describen composiciones farmacéuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para antagonizar los receptores de adenosina A2B, para tratar asma, diarrea, regulacion del tono del musculo liso, tratamiento de desordenes inflamatorios del tracto gastrointestinal, el tratamiento de la enfermedad de Alzheimer, de Parkinson, demencia, de presion, o dano cerebral traumático, enfermedades inflamatorias, y otras como esclerosis multiple, sepsis, osteoporosis, entre otros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15164999P | 1999-08-31 | 1999-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR029178A1 true AR029178A1 (es) | 2003-06-18 |
Family
ID=22539669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000104523A AR029178A1 (es) | 1999-08-31 | 2000-08-30 | Compuesto antagonista selectivo del receptor de adenosina a2b, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1208100B1 (es) |
JP (1) | JP3914434B2 (es) |
KR (1) | KR100502757B1 (es) |
CN (1) | CN1178940C (es) |
AR (1) | AR029178A1 (es) |
AT (1) | ATE236160T1 (es) |
AU (1) | AU760071B2 (es) |
BR (1) | BR0013673A (es) |
CA (1) | CA2383351C (es) |
DE (1) | DE60001969T2 (es) |
DK (1) | DK1208100T3 (es) |
ES (1) | ES2190422T3 (es) |
HK (1) | HK1049835B (es) |
IL (2) | IL148366A0 (es) |
MX (1) | MXPA02002262A (es) |
NO (1) | NO328489B1 (es) |
NZ (1) | NZ517546A (es) |
PT (1) | PT1208100E (es) |
TR (1) | TR200201132T2 (es) |
TW (1) | TWI262921B (es) |
WO (1) | WO2001016134A1 (es) |
ZA (1) | ZA200201650B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
US20020012946A1 (en) | 2000-02-23 | 2002-01-31 | Luiz Belardinelli | Method of identifying partial agonists of the A2A receptor |
US6770651B2 (en) | 2001-06-29 | 2004-08-03 | Venkata Palle | A2B adenosine receptor antagonists |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
WO2005009445A1 (en) * | 2003-07-22 | 2005-02-03 | Cv Therapeutics, Inc. | A1 adenosine receptor antagonists |
WO2005053695A1 (ja) * | 2003-12-04 | 2005-06-16 | Eisai Co., Ltd. | 多発性硬化症予防剤または治療剤 |
US7713982B2 (en) * | 2004-02-14 | 2010-05-11 | Smithkline Beecham Corporation | Xanthines with HM74A receptor activity |
JP2008516969A (ja) * | 2004-10-15 | 2008-05-22 | シーブイ・セラピューティクス・インコーポレイテッド | A2bアデノシン受容体アンタゴニストを使用した、気道のリモデリングおよび肺の炎症の予防および処置の方法 |
JP2008517063A (ja) | 2004-10-20 | 2008-05-22 | シーブイ・セラピューティクス・インコーポレイテッド | A2aアデノシンレセプターアゴニストの使用 |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
PL1989214T3 (pl) | 2006-02-03 | 2017-07-31 | Gilead Sciences, Inc. | Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów |
US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
EP3389664A4 (en) * | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF |
MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7810946L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | Metod att behandla kronisk obstruktiv luftvegssjukdom |
DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
WO1992011260A1 (en) * | 1990-12-21 | 1992-07-09 | Beecham Group Plc | Xanthine derivatives |
GB9210839D0 (en) * | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
-
2000
- 2000-08-28 NZ NZ517546A patent/NZ517546A/en unknown
- 2000-08-28 AT AT00971055T patent/ATE236160T1/de not_active IP Right Cessation
- 2000-08-28 WO PCT/US2000/040751 patent/WO2001016134A1/en not_active Application Discontinuation
- 2000-08-28 EP EP00971055A patent/EP1208100B1/en not_active Expired - Lifetime
- 2000-08-28 PT PT00971055T patent/PT1208100E/pt unknown
- 2000-08-28 BR BR0013673-5A patent/BR0013673A/pt not_active Application Discontinuation
- 2000-08-28 DE DE60001969T patent/DE60001969T2/de not_active Expired - Lifetime
- 2000-08-28 JP JP2001519700A patent/JP3914434B2/ja not_active Expired - Fee Related
- 2000-08-28 AU AU80348/00A patent/AU760071B2/en not_active Ceased
- 2000-08-28 TR TR2002/01132T patent/TR200201132T2/xx unknown
- 2000-08-28 ES ES00971055T patent/ES2190422T3/es not_active Expired - Lifetime
- 2000-08-28 MX MXPA02002262A patent/MXPA02002262A/es active IP Right Grant
- 2000-08-28 CA CA002383351A patent/CA2383351C/en not_active Expired - Fee Related
- 2000-08-28 CN CNB00813717XA patent/CN1178940C/zh not_active Expired - Fee Related
- 2000-08-28 IL IL14836600A patent/IL148366A0/xx active IP Right Grant
- 2000-08-28 DK DK00971055T patent/DK1208100T3/da active
- 2000-08-28 KR KR10-2002-7002718A patent/KR100502757B1/ko not_active IP Right Cessation
- 2000-08-30 AR ARP000104523A patent/AR029178A1/es active IP Right Grant
- 2000-09-21 TW TW089117772A patent/TWI262921B/zh not_active IP Right Cessation
-
2002
- 2002-02-25 IL IL148366A patent/IL148366A/en not_active IP Right Cessation
- 2002-02-27 ZA ZA200201650A patent/ZA200201650B/en unknown
- 2002-02-27 NO NO20020979A patent/NO328489B1/no not_active IP Right Cessation
-
2003
- 2003-03-14 HK HK03101920.0A patent/HK1049835B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU760071B2 (en) | 2003-05-08 |
BR0013673A (pt) | 2002-05-28 |
IL148366A0 (en) | 2002-09-12 |
NO328489B1 (no) | 2010-03-01 |
AU8034800A (en) | 2001-03-26 |
CN1377352A (zh) | 2002-10-30 |
HK1049835A1 (en) | 2003-05-30 |
CA2383351C (en) | 2005-11-01 |
NZ517546A (en) | 2003-10-31 |
DK1208100T3 (da) | 2003-06-30 |
TR200201132T2 (tr) | 2002-08-21 |
KR20020041419A (ko) | 2002-06-01 |
CA2383351A1 (en) | 2001-03-08 |
ES2190422T3 (es) | 2003-08-01 |
ZA200201650B (en) | 2003-05-28 |
HK1049835B (zh) | 2005-04-08 |
KR100502757B1 (ko) | 2005-07-22 |
NO20020979D0 (no) | 2002-02-27 |
EP1208100A1 (en) | 2002-05-29 |
ATE236160T1 (de) | 2003-04-15 |
JP2003508398A (ja) | 2003-03-04 |
JP3914434B2 (ja) | 2007-05-16 |
DE60001969D1 (de) | 2003-05-08 |
DE60001969T2 (de) | 2004-02-05 |
NO20020979L (no) | 2002-04-26 |
IL148366A (en) | 2006-12-10 |
EP1208100B1 (en) | 2003-04-02 |
MXPA02002262A (es) | 2002-09-30 |
CN1178940C (zh) | 2004-12-08 |
TWI262921B (en) | 2006-10-01 |
WO2001016134A1 (en) | 2001-03-08 |
PT1208100E (pt) | 2003-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR029178A1 (es) | Compuesto antagonista selectivo del receptor de adenosina a2b, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento | |
WO2004007481A3 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders | |
WO2002068406A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
CY1115484T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson | |
UY27092A1 (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
MY136034A (en) | New medicaments for the treatment of chronic obstructive pulmonary disease | |
IL146403A0 (en) | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | |
PT1259489E (pt) | Compostos azapoliciclicos condensados con arilo. | |
UY28374A1 (es) | Agentes terapéuticos | |
AR021893A1 (es) | Compuesto de 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanona sustituida , su uso para la manufactura de un medicamento en el tratamiento de algunos trastornos del sistema nervioso central y periférico y composiciones farmacéuticas que las contienen | |
UY26728A1 (es) | Derivados de la benzocicloalquilenilamina como antagonistas de los receptores muscarínicos | |
ES2160525B1 (es) | Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3 | |
SG137850A1 (en) | Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | |
MY140835A (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
TW200606164A (en) | New compounds | |
MX9300616A (es) | Compuestos antagonistas del receptor 5-hidroxitriptamina, proceso para su prepararcion y composicion farmaceutica que los contiene | |
EP1284257A3 (en) | Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter | |
MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
JP2005514457A5 (es) | ||
UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones | |
SE0102055D0 (sv) | New Compounds | |
UY26720A1 (es) | Derivados del pirrol | |
AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. | |
AR001769A1 (es) | Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |